ThermoGenesis Corp. and TotipotentSC Receive Approval for Phase Ib Clinical Trial of Res-Q 60 BMC

by Benzinga Staff
January 26, 2011 9:02 AM | 13 seconds read |
ThermoGenesis Corp. KOOL announced today they have received approval from Fortis Escorts' (New Delhi) Independent Ethics Committee to proceed with a Phase Ib clinical trial in patients suffering from Non-Reconstructable Critical Limb Ischemia utilizing ThermoGenesis' Res-Q 60 BMC system.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: NewsFDAHealth CareHealth Care Equipment
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!